QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leader in molecular diagnostics and life sciences, announced on November 6, 2026, that its shareholders have overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the company’s Managing Board. This decision was reached during an Extraordinary General Meeting of Shareholders held in Venlo, Netherlands.
Jonathan M. Pratt, who stepped into the role of Chief Executive Officer at QIAGEN on September 1, 2026, will now serve alongside Roland Sackers, the Chief Financial Officer, on the Managing Board. This appointment is a significant part of the company’s leadership transition following the resignation of Thierry Bernard.
Shareholders also voted to discharge Thierry Bernard from his duties as a member of the Managing Board. Bernard had served as CEO and a board member until September 1, 2026, when he stepped down from these roles. The discharge reflects the company’s gratitude for his service and leadership during his tenure.
About QIAGEN
QIAGEN N.V., headquartered in the Netherlands, is recognized globally for its Sample to Insight solutions. These solutions are pivotal in extracting and analyzing molecular information from biological samples, which are essential for understanding the fundamental components of life. The company’s technologies encompass the processing of DNA, RNA, and proteins from a variety of biological materials, including blood and tissue. Furthermore, QIAGEN provides assay technologies for biomolecule analysis and bioinformatics tools to interpret complex data, delivering actionable insights to its users. The company’s automation solutions help integrate these processes into efficient workflows, reducing time and costs for its clients.
QIAGEN serves a diverse clientele of over 500,000 customers worldwide. Its reach extends across the Life Sciences sector, including academia, pharmaceutical research and development, and industrial applications such as forensics. In the Molecular Diagnostics field, QIAGEN focuses on clinical healthcare, providing tools and technologies that aid in the diagnosis and treatment of diseases. As of September 30, 2026, QIAGEN employed approximately 5,400 individuals across more than 35 locations globally, underscoring its expansive operational footprint.
The company’s commitment to innovation and quality has positioned it as a trusted partner in the scientific community. By continuously advancing its technological capabilities and expanding its product offerings, QIAGEN aims to meet the evolving needs of its customers and maintain its leadership in the industry.
Forward-Looking Statements
The press release contains forward-looking statements as defined by U.S. federal securities laws. These statements pertain to QIAGEN’s products, development plans, regulatory approvals, market prospects, and anticipated business performance. Such statements are based on current expectations and assumptions and are subject to risks and uncertainties that could lead to significant deviations in actual outcomes. Potential risks include the success of new product developments, regulatory approvals, competitive pressures, shifts in customer demand and funding, economic and market conditions, supply chain challenges, cybersecurity threats, legal issues, and other risks outlined in QIAGEN’s latest Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. QIAGEN does not undertake any obligation to update these forward-looking statements unless required by law.
QIAGEN’s strategic focus on innovation and customer-centric solutions continues to drive its growth and success in the life sciences and diagnostics markets. The appointment of Jonathan M. Pratt as a Managing Director is expected to further strengthen the company’s leadership team and support its long-term strategic goals.
Footnotes:
- QIAGEN’s shareholders approved Jonathan M. Pratt’s appointment at an Extraordinary General Meeting. Source.
- Jonathan M. Pratt joined QIAGEN as CEO on September 1, 2026. Source.
- QIAGEN serves over 500,000 customers worldwide in various sectors. Source.
Featured Image: Megapixl @ Anyaberkut
